C
Cezary Szczylik
Researcher at Medical University of Warsaw
Publications - 291
Citations - 30393
Cezary Szczylik is an academic researcher from Medical University of Warsaw. The author has contributed to research in topics: Renal cell carcinoma & Cancer. The author has an hindex of 49, co-authored 274 publications receiving 27380 citations. Previous affiliations of Cezary Szczylik include Military Medical Academy & Cora.
Papers
More filters
Journal ArticleDOI
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Robert J. Motzer,Thomas E. Hutson,Piotr Tomczak,M. Dror Michaelson,Ronald M. Bukowski,Olivier Rixe,Stéphane Oudard,Sylvie Negrier,Cezary Szczylik,Sindy T. Kim,Isan Chen,Paul Bycott,Charles M. Baum,Robert A. Figlin +13 more
TL;DR: Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa.
Journal ArticleDOI
Sorafenib in advanced clear-cell renal-cell carcinoma.
Bernard Escudier,Tim Eisen,Walter M. Stadler,Cezary Szczylik,Stéphane Oudard,Michael Siebels,Sylvie Negrier,Christine Chevreau,Ewa Solska,Apurva A. Desai,Frederic Rolland,Tomasz Demkow,Thomas E. Hutson,Martin Gore,Scott Freeman,Brian Schwartz,M. Shan,Ronit Simantov,Ronald M. Bukowski +18 more
TL;DR: As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is associated with increased toxic effects.
Journal ArticleDOI
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg,Ian D. Davis,Jozef Mardiak,Cezary Szczylik,Eunsik Lee,John Wagstaff,Carlos H. Barrios,Pamela Salman,Oleg Gladkov,Alexander Kavina,J. J. Zarba,Mei Chen,Lauren McCann,Lini Pandite,Debasish F. Roychowdhury,Robert E. Hawkins +15 more
TL;DR: Pazopanib demonstrated significant improvement in PFS and tumor response compared with placebo in treatment-naive and cytokine-pretreated patients with advanced and/or metastatic RCC.
Journal ArticleDOI
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier,Anna Pluzanska,Piotr Koralewski,Alain Ravaud,Sergio Bracarda,Cezary Szczylik,Christine Chevreau,Marek Filipek,Bohuslav Melichar,Emilio Bajetta,Vera Gorbunova,Jacques-Olivier Bay,Istvan Bodrogi,Agnieszka Jagiełło-Gruszfeld,Nicola Moore +14 more
TL;DR: In this article, the authors investigated the combination treatment of the humanised anti-VEGF monoclonal antibody bevacizumab with interferon alfa, and reported a significant improvement in progression-free survival.
Journal ArticleDOI
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini,Elizabeth R. Plimack,Viktor Stus,Rustem Gafanov,Robert E. Hawkins,Dmitry Nosov,Frédéric Pouliot,Boris Alekseev,Denis Soulières,Bohuslav Melichar,Ihor Vynnychenko,Anna Kryzhanivska,Igor Bondarenko,Sergio J Azevedo,Delphine Borchiellini,Cezary Szczylik,Maurice Markus,Raymond S. McDermott,Jens Bedke,Sophie Tartas,Yen-Hwa Chang,Satoshi Tamada,Qiong Shou,Rodolfo F. Perini,Mei Chen,Michael B. Atkins,Thomas Powles +26 more
TL;DR: Treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression‐free survival, as well as a higher objective response rate, than treatment with sunitin ib among patients with previously untreated advanced renal‐cell carcinoma.